×

Betting On Biotech Blockbusters

With Amgen generating a new and potential blockbuster drug, should you try to get in on the action?

Investor sentiment toward beaten-down Amgen perked up markedly this week after the company reported better-than-expected results from a trial of its experimental bone-protecting drug in patients with advanced breast cancer.

The results galvanized investors who have weathered a steady drum-beat of bad news related to the safety of its flagship anemia drugs.

Symbol
Price
 
Change
%Change
EME
---

"The results were better than anticipated and support higher revenue potential than previously expected," says Geoffrey Porges, an analyst at Sanford Bernstein. "Since Zometa is the most powerful agent in the existing bisphosphonate class, this represents a real breakthrough and sets a high bar for future competitors from other classes."

Separately, Geoffrey Meacham, an analyst at J.P. Morgan, said the results were enough to warm the heart of even cynical investors.

Considering the exciting advances, should you try and get in on the action?

In my opinion if you own Amgen I’d trim some gains and take a victory lap, says Deutsche analyst Mark Schoenebaum. After these results I think the stock gets stuck in a range in the low $60’s.

______________________________________________________
Got something to to say? Send us an e-mail at fastmoney-web@cnbc.com and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send your e-mail to fastmoney@cnbc.com.

Trader disclosure: On July 9th, 2009, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Adami Owns (AGU), (BTU), (C), (GS), (INTC), (MSFT), (NUE); Finerman's Firm And Finerman Own (BAC) Preferred Shares; Finerman's Firm And Finerman Own (RIG); Finerman's Firm Owns (ELX) And (ELX) Puts; Finerman's Firm And Finerman Own (WFC) Preferred Shares, Finerman's Firm Is Short (WFC); Finerman's Firm Owns (DYN), (TGT), (MSFT), (PBR), (WMT); Finerman's Firm Is Short (XRT), (IYR), (IJR), (MDY), (SPY), (IWM), (USO), (USO); Seymour Owns (AA), (AAPL), (BAC), (C), (DBA), (EEM); Seygem Asset Management Is Short (FXI); Seymour Owns (MGM); Seygem Asset Management Owns (DO); Terranova Owns (OIH), (XBI), (ABT), (MSFT), (POT), (RIMM); Terranova Owns Crude Oil Futures

Terranova Works For (VRTS); Terranova Is Chief Alternatives Strategist Of Virtus Investment Partners, Ltd.; Terranova Is Co-Portfolio Manager Of The Virtus Diversifier PHOLIO

Virtus Diversifier PHOLIO Owns (IGE); (DBC); (DBV) , (ABD) Virtus Investment Partners Owns More Than 1% Of (ABD), (CBL), (CAL), (CLB), (DLR), (EXR), (IGE) (MEE), (DBC), (DBV), (DBA), (SKT), (TNB), (UA), (WBMD) ; Virtus Investment Partners Owns More Than 1% Of Seagate Tax Refund Rights; Virtus Investment Partners Owns More Than 1% Of St Mary Land & Exploration Co

For Mark Schoenebaum
Deutsche Bank And/Or Affiliates Owns 1% Or More Of (AMGN), (ACOR), (GILD), (UTHR), (BIIB)(AMGN), (ACOR), (GENZ), (UTHR), (DNDN) Are Investment Banking Clients Of DBSI
(GENZ), (GILD) Have Been Clients Of Deutsche Bank Securities Within Past Year And Received Non-Investment Banking Securities-Related Services